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ABSTRACT: In order to study the role of S1PRs in inﬂammatory skin disease, S1PR modulators are dosed orally and topically
in animal models of disease. The topical application of S1PR modulators in these models may, however, lead to systemic drug
concentrations, which can complicate interpretation of the observed eﬀects. We set out to design soft drug S1PR modulators as
topical tool compounds to overcome this limitation. A fast follower approach starting from the drug ponesimod allowed the
rapid development of an active phenolic series of soft drugs. The phenols were, however, chemically unstable. Protecting the
phenol as an ester removed the instability and provided a compound that is converted by enzymatic hydrolysis in the skin to the
phenolic soft drug species. In simple formulations, topical dosing of these S1PR modulators to mice led to micromolar skin
concentrations but no detectable blood concentrations. These topical tools will allow researchers to investigate the role of S1PR
in skin, without involvement of systemic S1PR biology.
KEYWORDS: S1PR, soft-drug, plasma stability, topical tool compound
Sphingosine-1-phosphate receptor (S1PR) agonists, such asﬁngolimod and ponesimod (Figure 1), initially activate
S1P receptors but subsequently trigger receptor internalization
and downregulation of signaling; shutting down the
sphingosine-1-phosphate signaling pathway. Fingolimod was
approved in 2010 for the treatment of relapsing/remitting
multiple sclerosis and is the only S1PR agonist approved to
date.1 It is eﬃcacious at low doses (0.5 mg/day) and at low
steady state systemic concentrations (Cmax 3.1 ng/mL).
Recently the potential for the S1PR pathway to be of
therapeutic use in the treatment of a range of diverse
inﬂammatory skin diseases has emerged.2−6 Some studies
have explored the skin biology of S1PR agonists by topical
application of these compounds in various animal models of
diseases such as atopic dermatitis,4 allergic dermatitis,5 and
psoriasis.6 Topical application can, however, also lead to
systemic eﬀects. Following penetration through the stratum
corneum, drugs will eventually distribute into the vasculature.
If the rate of absorption exceeds the rate of elimination, topical
dosing will lead to systemic drug exposure. Topical dosing of
potent drugs, such as ﬁngolimod, may lead to suﬃcient
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Figure 1. Selected S1PR modulators.
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systemic drug concentrations to elicit measurable biological
eﬀects, complicating the interpretation of such studies.
In order to remove the potential for systemic exposure, we
decided to develop a soft drug S1PR modulator.7,8 Soft drugs
are locally active, in this case in the skin, but are designed to
undergo rapid systemic metabolism to metabolites, which are
either inactive or rapidly cleared from systemic circulation.9
Due to ease of access of the diseased organ, many
dermatological diseases are ideally suited to treatment with
topical soft drugs, which can safely engage biological targets,
previously shown to lead to adverse side eﬀects, following oral
dosing.
Table 1. Optimization of the Thiazolidinone Core
aRacemic mixture. bReverse-phase HPLC method to determine the chromatographic hydrophobicity index (CHI): n of 1. cThe aqueous kinetic
solubility of the test compounds was measured using laser nephelometry: n of 1. dHuman S1PR1 activity was measured using a human PathHunter
β-Arrestin recruitment assay. All pIC50s reported in this table correspond to n ≥ 2, reported as their geometric mean.
Scheme 1a
aMethod A (i) 2-chloroacetyl chloride, TEA, THF, −78 °C to RT, 2
h; (ii) 1-isothiocyanatopropane, NaH, DMF, RT, 16 h. Method B (iii)
1-isothiocyanatopropane, CH2Cl2, RT, 2 h; (iv) 2-bromoacetyl
bromide, pyridine, CH2Cl2, 0 °C to RT, 1 h; (v) NaOAc, AcOH,
65 °C, 16 h; (vi) BBr3, CH2Cl2, −70 °C to 0 °C, 3 h.
Scheme 2a
a(i) R2NH2, CH2Cl2, RT, 1 h; (ii) 2-bromoacetyl bromide, pyridine,
CH2Cl2, 0 °C to RT, 2 h; (iii) NaOAc, AcOH, 65 °C, 16 h; (iv)
dicyanozinc, Pd(PPh3)4, DMA 100 °C, 1.5 h; (v) BBr3, DCM, −78
°C, 3 h then 0 °C, 3 h.
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In their paper describing ponesimod’s discovery, Bolli et al.
disclosed that phenols, such as compound 4a, although active
were unsuitable for progression, as an oral drug, due to high
clearance in both in vitro and in vivo experiments.10 The
authors speculated that the high clearance may be due to the
fact that phenols are well-known substrates for phase 2
metabolism conjugating enzymes.10 Glucuronidation is a
common phase II metabolism pathway that covalently
conjugates glucuronic acid, in a base-catalyzed process from
UDPGA (uridine-50-diphosphoglucuronic acid) to lipophilic
substrates via UGT enzymes (uridine-50-diphosphoglucuro-
nosyl transferases).11 Sulfation, another common phase II
metabolism pathway, covalently links a substrate to a sulfo
group (SO3), usually derived from 3′-phosphoadenosine-5′-
phosphosulfate (PAPS), via sulfotransferase enzymes.12 As the
glucuronide and sulfate metabolites are highly polar, and
therefore water-soluble, they subsequently undergo renal or
biliary elimination. Due to their aﬃnity for phase II
metabolism, phenols are commonly used motifs when
designing soft drugs.13,14 There is little evidence of clinically
relevant drug-related inhibition of glucuronidation or sulfation,
so the risk of drug−drug interactions is considered to be low.15
Accordingly we set out to utilize phase II metabolism pathways
as the major routes of clearance for our S1PR agonist soft
drugs.
Although 4a had been shown to be rapidly cleared, which
was conﬁrmed in our hands (Table 1), the compound
displayed poor aqueous solubility. Aqueous solubility is an
important parameter for topically applied drugs as it can
support use in higher water content formulations, such as a
creams, which may be preferred by patients over oily
formulations like ointments. We therefore set out to improve
the aqueous solubility of 4a.
Keeping the 3-chloro-4-hydroxybenzylidene motif from 4a
constant, we synthesized a series of phenols with diﬀerent
substituents to replace the 2-tolyl 4a motif with aromatic or
aliphatic groups (Scheme 1). Using Method A, the appropriate
aniline was reacted with 2-chloroacetyl chloride to give the
corresponding 2-chloro-N-phenylacetamide, which was con-
densed with 1-isothiocyanatopropane to give the required
Table 2. Eﬀect of Substituents on the Phenol
compound R1 X H S1PR1 pIC50
a Kinetic Solubility (μM)b pKa
c HLM Cld H Heps Cle stabilityf CHI logDg
4a Cl CH 7.4 79 6.8 1.6 8.4 6 3.8
9f Br CH 7.7 79 6.4 1.6 6.0 16 3.9
9g CF3 CH 7.5 14 6.6 1.0 4.2 10 3.8
9h CN CH <6.0 220 <0.5 20
9i H N 7.0 110 7.1 2.8 7.9 4 3.0
9j H CH 7.1 79 8.3 2.4 1.7 0 3.5
9k Me CH 7.6 78 8.5 2.8 31 3 3.8
9l i-Pr CH <6.0 79 8.6 12 3 4.3
aHuman S1PR1 activity was measured using a human PathHunter β-Arrestin recruitment assay. All pIC50s reported in this table correspond to n ≥
2, reported as their geometric mean. bThe aqueous kinetic solubility of the test compounds was measured using laser nephelometry: n = 1. cpKa was
determined using a potentiometric fast UV-metric titration method: n = 1. dIntrinsic clearance in human liver microsomes (mL/min/g): n = 1.
eIntrinsic clearance in human liver hepatocytes (mL/min/g): n = 1. f% decrease in purity when stored in DMSO solution for 28 days: n = 1.
gReverse-phase HPLC method to determine the chromatographic hydrophobicity index (CHI): n = 1.
Scheme 3a
a(i) Acid chloride (1 equiv), DMAP (0.05 equiv), TEA (1.2 equiv) in
CH2Cl2 at rt, 16 h; (ii) 2,2-dimethylpropanoic acid (1 equiv), DCC
(1.2 equiv), DMAP (0.2 equiv), DMF, 40 °C, 16 h.
Table 3. Eﬀect of Substitution at R1 and R2 on Skin S9 and
Chemical Stability
compound R1 R2
H Skin S9 (half-
life min)b
stability (%
decrease)c
ponesimod Cl >180 0
10a Me Me 7.3 0
10b Br Me 8.8 6.3
10c CF3 Me 8.3 1.4
10d Me CH2OMe a
10e Me CH2NMe2 a
10f Me CH2CH2OH 8.2 0
10g Me CH2CH2OMe 4.8
10h Me i-Pr 21
10i Me t-Bu >180
aUnstable after 24 h in DMSO solution: n = 1. bStability measured in
skin S9 over 180 min in the presence of enzymatic cofactors: n = 1. c%
loss in purity when stored in DMSO solution for 28 days: n = 1.
Table 4. Selectivity against S1PR1-4a
compound S1PR1 pIC50 S1PR2 pIC50 S1PR3 pIC50 S1PR4 pIC50
ponesimodb 8.2 <5.0 7.0 6.0
10a 7.6 <5.0 6.0 <5.0
9k 8.0c <5.0 6.1 <5.0
aS1PR1−4 activity was measured using a human PathHunter β-
Arrestin recruitment assay (n = 2). bS1PR1−4 activity reported in the
literature using a GTPγS assay.9 cThe potency of 9k on S1PR1 slightly
shifted to a higher value in this experiment, which is independent to
the experiments performed to establish the SAR (Table 2).
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thiazolidinone core 2a,b. Subsequent condensation with 3-
chloro-4-hydroxybenzaldehyde 3 generated compounds 4a,b.
Compounds 4c−g with aliphatic R1 groups used Method B,
where amines 1c−g were reacted with 1-isothiocyanatopro-
pane, then with 2-bromoacetyl bromide in the same reaction
vessel. The resulting thiazolidinone cores 2c−g were
condensed with 3-chloro-4-hydroxybenzaldehyde 3, and the
products 4c−g were obtained using preparatory HPLC.
Compound 4h was prepared by BBr3 demethylation of the
anisole 4b to give the corresponding phenol.
Compounds 9a−9e replaced the n-propyl group of 4a with
several small N-linked aliphatic substituents, while compounds
9f−l looked at eﬀects of substituents on the 4-hydroxybenzy-
lidene group (Scheme 2). The appropriately substituted
thiazolidin-4-one core 7a−d was synthesized utilizing a one-
pot, two-step reaction. Alkyl amines were reacted with 1-
isothiocyanato-2-methylbenzene 5 to give the resulting
thioureas 6a−d, which condensed with 2-bromoacetyl bro-
mide, followed by addition of pyridine to furnish the desired
thiazolidin-4-one. The thiazolidin-4-one cores 6a−d were
condensed with the 4-hydroxybenzaldehyde 3 to give 9a−d.
Compound 9e was synthesized by treatment of 9c with BBr3.
Compound 2a was reacted with 8f,g,i−l to furnish products
9f,g,i−l. Compound 9h was synthesized using a Negishi
coupling with dicyanozinc and palladium tetrakis from 9f.
The conﬁguration of the double bonds in ponisimod and 4a
were determined by X-ray crystallography.10 The HMBC and
NOESY data of ponesimod and 4a were compared with 9k and
10a (see Supporting Information). The HMBC data for the
alkene proton to the carbonyl carbon (H9−C3 or H9′−C3′) in
all cases was consistent and suggested a Z double bond
arrangement of the alkene bond (the size of the 1H−13C
coupling constant was estimated to be 6−7 Hz). The only
cross peaks observed in the NOESY experiments were between
the 2-tolyl and imine groups. These weak signals between the
respective methyl groups (see Supporting Information) were
also observed for ponesimod, 4a, 9k, and 10a. It may be
expected that if the imine was in the E conﬁguration that there
would have been cross peaks observed between the methyl of
the 2-tolyl group and the NCH2 protons of the imine group;
however, this was not observed. Taken together, the data was
consistent with the Z conﬁguration observed using X-ray
crystallography but did not conﬁrm it. Based on the analysis of
analogous compounds 4a−h, 9a−l, and 10a−i were assigned
to the Z,Z-isomer, unless stated otherwise.
Compounds 4c−h and 9a−e were designed to improve
solubility by reducing logD or aromatic ring count.16 Although
the CHIlogD values were lower or equivalent for 4d, 4e, 4g,
and 9a−e, the compounds did not show an improvement in
aqueous solubility (Table 1). Reducing the aromatic ring count
in 4c−e and 4g also failed to improve aqueous solubility, while
4f gave an improvement in aqueous solubility 250 μM possibly
due to a 3-log unit reduction in CHIlogD but had a pIC50 of
<6.0. The addition of a 2-phenol group into the R1 position,
compound 4h, lowered the CHIlogD by 1.1 units and
improved aqueous solubility to 220 μM. Two of the changes
to the 2-propylimino group showed an improvement in
aqueous solubility. Compound 9a with a 2-oxetan-3-ylimino
group moderately increased solubility to 150 μM, compared to
79 μM for 4a. Compound 9e gave an improvement in aqueous
solubility (>250 μM) presumably due to the addition of the
polar hydroxyl-group and the commensurate reduction in
CHIlogD, but unfortunately, the compound had a pIC50 of
<6.0. The fact that 9a improves aqueous solubility and was
equipotent identiﬁes the 2-oxetan-3-ylimino group as a
potentially useful change to incorporate in the design of future
compounds.
Having examined two of the vectors oﬀ the thiazolidin-4-one
core, we turned our attention to the benzylidene substituent to
optimize activity, aqueous solubility, and hepatic metabolism.
For reason of synthetic expediency, we kept the 2-tolyl and n-
propyl groups in place with the intention of combining the
optimum substituents in subsequent design rounds. We
therefore synthesized a series of phenols (9f−9l) using the
method shown in Scheme 2. Compounds 9f−9l contained a
range of electron withdrawing and donating groups ortho to the
4-phenol of the benzylidene substituent. Compounds 9f, 9g,
and 9i−9k were largely equipotent to 4a, while 9h and 9l had a
pIC50 of <6.0, presumably in the case of 9l due to increased
steric bulk (Table 2). The triﬂuoromethyl group of 9g had low
aqueous solubility, while 9f and 9h−9l had acceptable
solubility.
As soft drugs must be rapidly cleared systemically and
phenols commonly undergo phase 2 metabolism, we used
human hepatocytes (H Heps) to study this potential route of
metabolism. We sought to obtain clearance rates of greater
than 85% human liver blood ﬂow (>4.8 mL/min/g); data
shown in Table 2. We then measured intrinsic clearance in
human liver microsomes (HLM) to determine if phase 1
metabolism was contributing to the observed intrinsic
clearance in hepatocytes. As glucuronidation is a base-catalyzed
process, where conserved carboxylate and histidine residues
facilitate the deprotonation of the phenol, we expected to see
an eﬀect of the pKa of the phenolic hydrogen on the rate of
hepatic clearance.14 We explored the eﬀect of the phenol pKa
on hepatic clearance with a set of ortho-substituents and a
Figure 2. (a) Metabolite identiﬁcation of (Z,Z)-10a in human skin S9 fraction (n = 1). (b) Metabolite identiﬁcation of (Z,Z)-9k and (Z,E)-9k in
human hepatocytes (n = 1). (c) Depiction of the enzymatic hydrolysis of (Z,Z)-10a and the hepatic metabolism of (Z,Z)-9k and (Z,E)-9k.
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meta-pyridine (Table 2). Electron-withdrawing groups did
reduce the pKa of the phenol 4a, and 9f−i have increased
hepatic clearance rates vs unsubstituted 9j. However, weakly
electron-donating groups demonstrated an even greater
increase in hepatic clearance rates (9k and 9l) despite the
expected increase in pKa. For this phenolic scaﬀold, ortho-
substituents led to an increase in glucuronidation rate in all
cases and was independent of phenolic pKa.
Although several compounds shown in Table 2 satisfy the
rapid clearance requirements of a soft drug and retain primary
activity, none were suitable for progression into in vivo studies
due to chemical stability liabilities. Analysis of the originally
pure compounds shown in Table 1, after being in DMSO
solution for 28 days, showed a range of purities. Compounds
with electron-withdrawing groups ortho to the phenol (4a, 9f−
h) were the least stable with a 6−20% impurity formed over 28
days. Compounds with neutral or donating groups in the ortho
position (9j−l) were more stable, in some cases giving
compounds that were stable over a 28-day period (9j). The
instability in solution represented a major development hurdle
as topical drugs are usually stored in solution or suspensions
(cream, ointment, paste, lotion, or gels), rather than in solid
form, as is the case for oral drugs. We turned our attention to
identifying the impurity and preventing its formation.
We conducted NMR studies of compound 9h after
incubation in DMSO-d6 for 6 months (see Supporting
Information for HMBC and NOESY spectra). In that time
the impurity had increased from 20% to 32% of the mixture
based on the integration of H18 vs H18′ in the 1H NMR
spectrum. The NOESY spectrum of the mixture indicated no
changes in the arrangement of the imine (no correlation was
observed between H11−H19 or H11′−H19′). HMBC experi-
ments measuring the three bond coupling constant between
H9−C3 and H9′−C3′ were analyzed and conﬁrmed that the
double bond in the major component (68%) had a coupling
constant of 6.4 Hz indicating a Z arrangement, while in the
minor component (32%) the coupling was measured at 11.9
Hz indicating an E arrangement.
As we expected them to be signiﬁcantly less active due to the
orientation of the phenol group, no examples of (Z,E)
compounds were isolated.
The association between electron withdrawing groups and
the rate of the isomerization could be explained by the
requirement for a base-catalyzed isomerization mechanism
(see Supporting Information for proposed mechanism). We
hypothesized that protecting the phenol via alkylation (as in
ponesimod) or acylation would remove the ability of the
conjugated pi-system to isomerize the double bond from Z to
E. To test this theory we synthesized compounds 10a−i via
esteriﬁcation of the parent phenol (Scheme 3). Reaction of
phenol 9k,f,g with the corresponding acid chloride gave
compounds 10a−h. Reaction of phenol 9k with dimethylpro-
panoic acid and DCC gave compound 10i.
We were delighted to discover that acylation blocked
isomerization and 10a,f shown in Table 3 did not isomerize
after being in a DMSO solution for 28 days. Electron-
withdrawing groups at R1 (10b,c) did lead to a slight decrease
in purity (6.3 and 1.4%, respectively) over the 28-day duration
of this experiment, but the degradation product was due to
hydrolysis of the ester to the phenol rather than isomerization
of the double bond. Decomposition studies used 1H NMR to
monitor the increase in the acetic acid methyl group peak over
28 days (see Supporting Information). Compound 10a showed
no hydrolysis or isomerization. However, the chemical stability
was poor when heteroatoms were alpha to the carbonyl of the
acetate group 10d,e, and these compound degraded on
standing within 24 h, preventing full characterization. Chemi-
cally, instability was not an issue when the heteroatoms were in
the beta position 10f,g.
We expected the ester to be unstable in skin, which would
liberate the phenol to engage the receptor in the target tissue.
Determining skin stability using human skin S9 fraction (Table
3) demonstrated compounds 10a−c,f,g underwent rapid
metabolism. Bulking out the ester with i-Pr 10h or t-Bu 10i
gave longer half-lives as expected.
Unfortunately, acylation of 9k led to a decrease in aqueous
solubility, for example, 10a (39 μM) and 9k (79 μM). This
could be improved by adding polar groups as in 10f (79 μM);
however, solubility only improved to the level of phenol 4a and
is still lower than what is desirable in a topical drug. Our
identiﬁcation of the propensity for the phenol series to
isomerize meant they were unsuitable for development as tool
compounds or potential drugs. The acylated series does not
have the desired solubility of a potential drug but is suitable for
use as a topical tool.
Compound 10a was selected for further study, due its ease
of synthesis, stability to degradation in solution, and instability
in skin.
The selectivity of (Z,Z)-10a and (Z,Z)-9k across S1PR1−4
was determined (Table 4). As with ponesimod,10 both (Z,Z)-
10a and (Z,Z)-9k were most active against S1PR1, with >40-
and >80-fold selectivity, respectively, over the other S1PR
isoforms measured. Compounds (Z,Z)-10a and (Z,Z)-9k were
equipotent. The reactivity of the exocyclic double bond of
(Z,Z)-10a was examined using a glutathione trapping experi-
ment in human liver microsomes; no evidence of glutathione
adducts or derivatives was observed (see Supporting
Information).
To demonstrate (Z,Z)-10a is a suitable tool for in vivo
experiments, a topical pharmacokinetic experiment in mice
(see Supporting Information) using 22.5 μL of 1% propylene
glycol/ethanol 7/3 formulation was carried out. At 2 and 8 h
time points, (Z,Z)-10a concentrations in blood were below the
lower limit of quantiﬁcation (LLoQ). Compound (Z,Z)-10a’s
concentrations in blood were 8.8 μM (2 h) and 4.9 μM (8 h).
Compound (Z,Z)-9k’s concentrations were below the LLoQ in
blood at both time points and 134 μM (2 h) and 101 μM (8 h)
in the skin. Compound (Z,Z)-9k is present in the skin of mice
at >10,000-fold above the IC50 demonstrating that the
modulator is likely to be present at suﬃcient concentration
to inhibit local S1PR1. Compound (Z,Z)-10a is also present in
the skin of mice at >350-fold above the IC50 and will also be
able to locally inhibit S1PR1.
Metabolite identiﬁcation of (Z,Z)-10a using incubation with
human skin S9 fraction conﬁrmed that the expected phenol
(Z,Z)-9k was obtained after hydrolysis of the ester group: no
other metabolites were observed (Figure 2a). Based on the
stability of (Z,Z)-9k in DMSO over 28 days (Table 2), it is
likely this hydrolysis is enzymatically driven. We then
performed metabolite identiﬁcation studies using (Z,Z)-9k in
human hepatocytes to conﬁrm the routes of clearance of our
S1PR1 modulators. As before, (Z,Z)-9k isomerizes into (Z,E)-
9k in solution; Figure 2b shows the disappearance of parent
phenol (both (Z,Z)-9k orange and (Z,E)-9k green isomeric
forms) and identiﬁes the glucuronide conjugation product,
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hydroxylation products, and hydroxylation with sulfation
metabolites.
In conclusion, we have used a fast follower approach to
identify several highly cleared and active phenolic S1PR1
modulators. Many of the phenol soft drugs were unstable in
solution due to isomerization. We were able to prevent this
isomerization by acylation of the phenol, to deliver chemically
stable chemical tools. The strategy underpinning our S1PR1
soft drug modulators is illustrated in Figure 2c. When (Z,Z)-
10a is applied to the skin of mice, it should be enzymatically
hydrolyzed to give (Z,Z)-9k. At this point, 9k can bind to
S1PR1 in the epidermis causing receptor internalization and
degradation. Compound (Z,Z)-9k will also start to slowly
isomerize to (Z,E)-9k. The mixture of isomers of 9k would
then enter the bloodstream and be distributed to the liver,
where it would be rapidly metabolized and cleared. The
hepatic intrinsic clearance rate for phenol (Z,Z)-9k, 31 mL/
min/g (Table 2), would correspond to 97% liver blood ﬂow if
there is a good in vitro to in vivo correlation, predicting that a
single pass through the liver could eliminate the majority of the
drug, greatly reducing the risk of systemic on-target toxicities,
which to date have limited the use of S1PR modulators.
Compound (Z,Z)-10a provides the community with a
valuable new tool that will enable targeted studies of S1PR
biology in skin, lung, or other suitable tissues.
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tetrahydrofuran; DMF, dimethylformamide; CHI, chromato-
graphic hydrophobicity index; HLM, human liver microsomes;
DMSO, dimethyl sulfoxide; Hz, hertz; DMAP, dimethylami-
nopyridine; DCC, N,N′-dicyclohexylcarbodiimide; DMA,
dimethylacetamide; HMBC, Heteronuclear Multiple Bond
Correlation; HSQC, Heteronuclear Single Quantum Correla-
tion; NOESY, Nuclear Overhauser Eﬀect Spectroscopy
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